# Professional Review: TaViT V3.2 Architecture

## Overall Assessment

TaViT (Treatment-Aware Trajectory Vision Transformer) is a **3.06M‑parameter** transformer that predicts glioma tumour volume trajectories (WT, TC, ET) from longitudinal MRI sequences conditioned on treatment history and molecular markers. The model is well‑structured, clearly documented, and achieves strong results on a small multi‑centre dataset (150 patients, 571 scans) with WT R²=0.917, TC R²=0.957, ET R²=0.959.

Below I summarise **what is already good** and **what could be improved** to push performance further.

---

## What Is Already Good

### 1. Multi‑modal, Clinically Relevant Inputs
TaViT fuses three distinct sources:
- **MRI visual features** (2816‑D nnU‑Net embedding)
- **Time‑varying treatment vector** (8‑D per scan)
- **Static molecular markers** (26‑D binary)
- **Time since diagnosis**

This goes beyond most prior works that use only imaging. The treatment ablation (+23.7% improvement) confirms the value of this design.

### 2. Handles Irregular Time Sampling
Patients have 2–6 scans at irregular intervals. Padding + mask + sinusoidal positional encoding allows the transformer to work with variable‑length, non‑equispaced sequences – a real‑world necessity.

### 3. Multi‑task Loss with Biological Priors
- **L_vol** (primary volume prediction)
- **L_delta** (forces learning of tumour dynamics)
- **L_cls** (PROG/STABLE/RESP trajectory classification)
- **L_smooth** (penalises unrealistically large jumps)

This combination improves both accuracy and biological plausibility.

### 4. Very Efficient Parameter Count
Only **3.06M trainable parameters** – far smaller than standard ViTs – yet converges in ~120 epochs on a small dataset. This makes deployment in clinical settings feasible.

---

## What Could Be Improved (with References)

### 1. Attention Design Does Not Explicitly Use Time Distance

**Current:** Standard self‑attention with 8 heads and 4 layers, using only additive sinusoidal time embeddings.

**Issue:** Attention weights depend only on learned token similarities, not directly on the *time interval* between scans. A scan at day 90 and day 900 get treated similarly if their features are alike.

**Improvement:** Use **time‑distance aware attention** where the attention score is modulated by the actual time gap (e.g., continuous time embeddings or a learnable time decay).  

*Reference:* Time‑distance vision transformers improved lung cancer diagnosis AUC from 0.734 to 0.786 by scaling attention with temporal distance (SPIE Medical Imaging 2022).

**Expected gain:** Better handling of long vs short gaps → lower MAE, especially for patients with irregular follow‑up.

---

### 2. No Pre‑training – Fully Random Initialisation

**Current:** All weights trained from scratch on only 150 patients.

**Issue:** 150 patients is small for a transformer, even with only 3M params. The nnU‑Net embeddings are fixed but the transformer projection layers are randomly initialised.

**Improvement:** Use **self‑supervised pre‑training** on a large public brain MRI corpus (e.g., full BraTS or TCGA) before fine‑tuning on your dataset.

*References:*  
- LTSA (Longitudinal Transformer for Survival Analysis) pre‑trained on fundus images then fine‑tuned on small cohorts → outperformed single‑image baselines (npj Digital Medicine 2024).  
- 3DINO (self‑supervised 3D ViT) on 100k+ scans transfers well to downstream tasks (npj Digital Medicine 2025).

**Expected gain:** Improved feature extraction for TC/ET subregions – potentially +0.02–0.05 R².

---

### 3. Treatment Integration Could Be More Expressive

**Current:** `concat(scan_proj, treat_proj)` → MLP fusion. Works, but is relatively simple.

**Improvement:** Use **gated or FiLM‑style modulation** where treatment vectors *adaptively scale* the scan features instead of being concatenated. This allows treatment to “gate” which visual features matter.

*Reference:* Feature‑wise linear modulation (FiLM) has been used in medical imaging to condition predictions on auxiliary variables (e.g., patient age, treatment). Also similar to adaptive layer norm in conditional transformers.

**Expected gain:** Small but consistent improvement in volume prediction, especially for patients with mixed treatment regimens.

---

### 4. Evaluation Missing Key Dynamic Metrics

**Current:** R², MAE, and trajectory accuracy (39.1% vs 33.3% baseline).

**Missing:** 
- **Directional accuracy** – how often the predicted volume change (increase/decrease) matches the true change.
- **Uncertainty quantification** – clinicians need confidence intervals.

**Improvement:**  
- Report **Δ‑sign accuracy** (% of predictions where sign(Δpred) = sign(Δtrue)).  
- Add **Monte Carlo dropout** or a **Bayesian output layer** to produce prediction intervals.

*Reference:* Variational temporal deconfounder networks (J Biomed Inform 2025) and Causal Transformer (arXiv:2204.07258) both provide uncertainty estimates for clinical time series.

**Expected gain:** Makes the model more clinically actionable, not just numerically better.

---

### 5. Limited Interpretability

**Current:** Only performance metrics reported.

**Improvement:**  
- **Attention heatmaps** for example patients (PROG, STABLE, RESP) to show which scans the model focuses on.  
- **Grad‑CAM or Integrated Gradients** applied to the fusion layer to identify which MRI features drive volume predictions.

*Reference:* Grad‑CAM used for tumour growth modelling (BMC Cancer 2025) provides 3D visual feedback.

**Expected gain:** Builds trust with clinicians and helps debug failure cases.

---

### 6. Data Augmentation & External Validation

**Current:** Only real 150 patients, 3‑fold CV.

**Improvement:**  
- **Embedding‑space augmentation:** random masking, channel noise, temporal dropout.  
- **Generate synthetic trajectories** using a physics‑guided model (e.g., TumorFlow) to augment training.  
- **External validation** on a separate glioma cohort (e.g., BraTS longitudinal data) if available.

*Reference:* TumorFlow: Physics‑Guided Longitudinal MRI Synthesis (MCML 2026).

**Expected gain:** Improved generalisation and robustness to missing data.

---

## Summary Table – Priority Improvements

| Priority | Improvement | Expected Benefit |
|----------|-------------|------------------|
| ★★★ | Time‑distance aware attention | Better handling of irregular intervals, lower MAE |
| ★★★ | Self‑supervised pre‑training (3DINO / LTSA style) | Higher R² for TC/ET, better small‑sample generalisation |
| ★★★ | Attention + Grad‑CAM visualisation | Clinical interpretability, trust, debugging |
| ★★☆ | Directional accuracy & uncertainty intervals | Clinically useful outputs |
| ★☆☆ | Gated / FiLM treatment fusion | Small, consistent volume prediction gain |
| ★☆☆ | External validation & synthetic augmentation | Robustness, generalisation |

---

## Final Verdict

**TaViT V3.2 is already a strong, well‑engineered model** that cleverly integrates multiple clinical data streams into a lightweight transformer. Its reported R² values (0.917–0.959) are impressive given the small dataset.

However, the architecture can be **pushed further** by:
- making attention truly time‑distance aware,
- leveraging large‑scale self‑supervised pre‑training,
- adding uncertainty and directional metrics,
- and improving interpretability.

These changes would elevate TaViT from a strong research prototype to a **clinically deployable tool** for personalised glioma prognosis.